Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tumour infiltrating lymphocytes - National Institutes of Health/Bristol-Myers Squibb

Drug Profile

Tumour infiltrating lymphocytes - National Institutes of Health/Bristol-Myers Squibb

Latest Information Update: 15 Jan 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Class Cancer vaccines; Cell therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer; Non-small cell lung cancer; Renal cancer

Most Recent Events

  • 11 Dec 2000 A clinical study has been added to the Cancer therapeutic trials section
  • 24 Sep 1996 Investigation in Non-small cell lung cancer in Italy (IV)
  • 24 Sep 1996 A study has been added to the immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top